Research programme: anti-infectives - Cengent Therapeutics

Drug Profile

Research programme: anti-infectives - Cengent Therapeutics

Alternative Names: ALF inhibitors research programme - Cengent Therapeutics; Zinc metalloprotease inhibitors - Cengent

Latest Information Update: 29 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cengent Therapeutics
  • Class Small molecules
  • Mechanism of Action Anthrax toxin inhibitors; Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anthrax

Most Recent Events

  • 29 Aug 2007 Discontinued - Preclinical for Anthrax in USA (unspecified route)
  • 24 Nov 2003 Preclinical data from a media release have been added to the Bacterial Infections pharmacodynamics section
  • 27 May 2003 Cengent Therapeutics' ALF inhibitors are available for licensing and further development (http://www.cengent.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top